VEGFR2-targeted contrast agent BR55
Term · Oncology and biomedicine · MLC-T-ONC-017479
A lipopeptide-based, vascular endothelial growth factor receptor 2 (VEGRF2) -targeted contrast agent with the property of molecular imaging of angiogenesis. BR55 is prepared by incorporation of a biospecific heterodimer peptide into the perfluorobutane-containing lipid-shelled microbubble membrane; the peptide specifically binds to VEGFR2 expressed on tumoral vascular endothelium allowing ultrasound imaging of the sites of active angiogenesis.
| Identifier | MLC-T-ONC-017479 |
|---|---|
| Field | Oncology and biomedicine |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-017479",
"term": "VEGFR2-targeted contrast agent BR55",
"field": "Oncology and biomedicine",
"definition": "A lipopeptide-based, vascular endothelial growth factor receptor 2 (VEGRF2) -targeted contrast agent with the property of molecular imaging of angiogenesis. BR55 is prepared by incorporation of a biospecific heterodimer peptide into the perfluorobutane-containing lipid-shelled microbubble membrane; the peptide specifically binds to VEGFR2 expressed on tumoral vascular endothelium allowing ultrasound imaging of the sites of active angiogenesis.",
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/vegfr2-targeted-contrast-agent-br55/"
}
Record 17,168 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.